{"orpha":88673,"name":"Hepatocellular carcinoma","type":"Clinical group","group":"Group of disorders","status":"active","flags":[],"synonyms":["HCC"],"definition":"Hepatocellular carcinoma is a primary hepatic cancer derived from well-differentiated hepatocytes. It is more frequent in adults than in childhood. Symptoms are hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure.","note":null,"url":"https://raremap.alftech.space/d/ORPHA-88673/","orphanet_url":"https://www.orpha.net/en/disease/detail/88673","names":{"fr":{"name":"Carcinome hépatocellulaire","synonyms":["CHC","HCC"],"definition":"Carcinome hépatocellulaire primaire dérivé d'hépatocytes bien différenciés. Il est plus fréquent chez les adultes que chez les enfants. Les symptômes sont une masse hépatique, des douleurs abdominales et, à un stade avancé, un ictère, une cachexie et une insuffisance hépatique."},"de":{"name":"Hepatozelluläres Karzinom","synonyms":["HCC","Leberzellkarzinom"],"definition":"Der Leberzellkrebs ist ein primärer, von gut differenzierten Hepatozyten hergeleiteter Leberkrebs. Er tritt häufiger bei Erwachsenen als bei Kindern auf. Symptome sind eine Gewebsmasse im Bereich der Leber, Leibschmerzen und, im fortgeschrittenen Stadium, Ikterus, Kachexie und Leberinsuffizienz."},"es":{"name":"Carcinoma hepatocelular","synonyms":["HCC"],"definition":"El carcinoma hepatocelular es un cáncer hepático primario derivado de hepatocitos bien diferenciados. Es más frecuente en la edad adulta que en la infancia. Los síntomas son una masa hepática, dolor abdominal y, en etapas avanzadas, ictericia, caquexia e insuficiencia hepática."},"it":{"name":"Carcinoma epatocellulare","synonyms":["HCC"],"definition":"Il carcinoma epatocellulare è un cancro epatico primitivo derivato da epatociti ben differenziati. È più frequente negli adulti rispetto ai bambini. I sintomi comprendono la presenza di una massa epatica, il dolore addominale e, negli stadi avanzati, ittero, cachessia e insufficienza epatica."},"nl":{"name":"Hepatocellulair carcinoom","synonyms":["HCC"],"definition":"Een primaire kanker van lever, afgeleid van goed gedifferentieerde hepatocyten. Het komt vaker voor bij volwassenen dan bij kinderen. Symptomen zijn massa van lever, abdominale pijn, en in vergevorderde stadia geelzucht, cachexie en leverfalen."},"pt":{"name":"Carcinoma hepatocelular","synonyms":["HCC"]},"pl":{"name":"Rak wątrobowokomórkowy","synonyms":["HCC"]},"cs":{"name":"Hepatocelulární karcinom","synonyms":["HCC"]},"uk":{"name":"Гепатоцелюлярна карцинома","synonyms":["HCC"],"definition":"Hepatocellular carcinoma is a primary hepatic cancer derived from well-differentiated hepatocytes. It is more frequent in adults than in childhood. Symptoms are hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure."},"zh":{"name":"肝细胞癌","synonyms":["HCC"]},"tr":{"name":"Hepatosellüler karsinom","synonyms":["HCC"]}},"xrefs":[{"source":"OMIM","code":"114550","qualifier":"E","icd_relation":null,"validated":true},{"source":"ICD-10","code":"C22.0","qualifier":"E","icd_relation":"specific","validated":true},{"source":"ICD-11","code":"2C12.02","qualifier":"E","icd_relation":"specific","validated":true,"icd11_uri":"1294035808"},{"source":"MONDO","code":"0007256","qualifier":"E","icd_relation":null,"validated":true},{"source":"MONDO","code":"7256","qualifier":"E","icd_relation":null,"validated":true},{"source":"MeSH","code":"D006528","qualifier":"E","icd_relation":null,"validated":true},{"source":"UMLS","code":"C2239176","qualifier":"E","icd_relation":null,"validated":true},{"source":"MedDRA","code":"10049010","qualifier":"E","icd_relation":null,"validated":true}],"associations":[],"incoming_associations":[],"preferential_parent":{"orpha":250908,"name":"Rare neoplastic disease"},"parents":[{"orpha":424936,"name":"Carcinoma of liver and intrahepatic biliary tract","classifications":[183,202]},{"orpha":506210,"name":"Rare disorder potentially indicated for liver transplant","classifications":[233]}],"children":[{"orpha":210159,"name":"Adult hepatocellular carcinoma","type":"Disease"},{"orpha":33402,"name":"Pediatric hepatocellular carcinoma","type":"Disease"}],"genes":[],"genes_via_subtypes":[],"inheritance":["Not applicable"],"onset":["All ages"],"prevalence":[{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":6.2,"area":"United States","status":"Validated","source":"25142309[PMID]_SEER Surveillance Epidemiology and End Results 1973-2011[OTHER]"},{"type":"Point prevalence","qualification":"Value and class","class":"1-5 / 10 000","value":15.0,"area":"Europe","status":"Validated","source":"European Medicines Agency 2017[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":6.264,"area":"France","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.106,"area":"United Kingdom","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":5.129,"area":"Germany","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":5.212,"area":"Spain","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":9.266,"area":"Italy","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-5 / 10 000","value":15.0,"area":"Greece","status":"Validated","source":"22537432[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":5.0,"area":"Canada","status":"Validated","source":"22537432[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":5.0,"area":"Oceania","status":"Validated","source":"22537432[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-5 / 10 000","value":12.5,"area":"Latin America","status":"Validated","source":"22537432[PMID]_18666317[PMID]_ ORPHANET"},{"type":"Annual incidence","qualification":"Value and class","class":"1-5 / 10 000","value":35.0,"area":"China","status":"Validated","source":"12095924[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-5 / 10 000","value":29.0,"area":"Japan","status":"Validated","source":"12095924[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-5 / 10 000","value":49.0,"area":"Korea, Republic of","status":"Validated","source":"12095924[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"6-9 / 10 000","value":99.0,"area":"Mongolia","status":"Validated","source":"12095924[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-5 / 10 000","value":16.0,"area":"Africa","status":"Validated","source":"18666317[PMID]_20616577[PMID]_22537432[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":3.221,"area":"Europe","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":5.296,"area":"Austria","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.275,"area":"Belgium","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.697,"area":"Bulgaria","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.762,"area":"Croatia","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.979,"area":"Czech Republic","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.487,"area":"Estonia","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":3.382,"area":"Finland","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.278,"area":"Iceland","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.045,"area":"Ireland","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.933,"area":"Latvia","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.146,"area":"Lithuania","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.627,"area":"Norway","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 1 000 000","value":0.925,"area":"Poland","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.345,"area":"Portugal","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.762,"area":"Slovakia","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":6.649,"area":"Switzerland","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.127,"area":"Netherlands","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"}],"phenotypes":null}